Concert Pharma

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Concert Pharmaceuticals is a clinical-stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with the potential for efficacy and safety, while greatly reducing R&D risk, time, and expense.

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q1 2021 Results - Earnings Call Transcript

Concert (CNCE) delivered earnings and revenue surprises of -1.52% and -99.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Concert Pharmaceuticals (CNCE) Reports Q1 Loss, Lags Revenue Estimates

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert reports financial results for the first quarter of 2021.

Concert Pharmaceuticals Reports First Quarter 2021 Financial Results

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--The Company will host a conference call and webcast on May 4, 2021, to discuss its first quarter 2021 financial results and provide a business update.

Concert Pharmaceuticals to Report First Quarter 2021 Results on May 4, 2021

Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Concert Pharmaceuticals (CNCE) Report Negative Q1 Earnings? What You Should Know

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q4 2020 Results - Earnings Call Transcript

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert reports financial results for the year ended December 31, 2020.

Concert Pharmaceuticals Reports 2020 Financial Results and Provides Update on Clinical Programs

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--The Company will host a conference call and webcast on February 25, 2021, to discuss 2020 financial results and provide a business update.

Concert Pharmaceuticals to Report Full Year 2020 Results on February 25, 2021

The company's experimental schizophrenia drug flopped in a phase 2 study.

Why Concert Pharmaceuticals Stock Cratered Today

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert announced its Phase 2 trial to evaluate CTP-692 as an adjunctive treatment in patients with schizophrenia did not meet the primary endpoint.

Concert Pharmaceuticals Announces Results from CTP-692 Phase 2 Trial in Patients with Schizophrenia

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q3 2020 Results - Earnings Call Transcript

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will host a conference call and webcast today at 8:30 a.m. ET to provide an update on the Company and discuss third quarter 2020 results.

Concert Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Company Update

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert initiated THRIVE-AA1, a Phase 3 study to evaluate the efficacy and safety of CTP-543 in adults with moderate to severe alopecia areata.

Concert Pharmaceuticals Initiates THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert presented initial data from an ongoing long-term, open-label extension study of CTP-543 in patients with alopecia areata at EADV.

Concert Pharmaceuticals Presents CTP-543 Data from Long-Term Extension Study in Alopecia Areata During Late-Breaking Session at EADV Congress

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will host a conference call and webcast on November 5, at 8:30 AM to discuss third quarter financial results and provide a business update.

Concert Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 5, 2020

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Key findings of the survey show that patients with alopecia areata suffer significantly increased burden of illness.

Concert Pharmaceuticals Announces Publication on Alopecia Areata Burden of Disease in Journal of Investigative Dermatology

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--The EADV presentation will highlight new CTP-543 data from an ongoing open label extension study in patients with moderate to severe alopecia areata.

Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2020 EADV Virtual Congress

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert completed enrollment in its Phase 2 trial evaluating CTP-692 as an adjunctive treatment in patients with schizophrenia.

Concert Pharmaceuticals Completes Enrollment in CTP-692 Phase 2 Trial in Patients with Schizophrenia

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert to participate in a fireside chat with Jason Butler at The JMP Securities CNS Forum.

Concert Pharmaceuticals to Present at The JMP Securities CNS Forum

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q2 2020 Results - Earnings Call Transcript

Concert (CNCE) delivered earnings and revenue surprises of 39.71% and 63770.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Tops Revenue Estimates

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will host a conference call and webcast today at 8:30 a.m.

Concert Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Company Update

Will Concert Pharmaceuticals (CNCE) Report Negative Q2 Earnings? What You Should Know

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 6, 2020

Cardiff Oncology

Intellicheck

Recro Pharma

Veritiv

Today also marked the beginning of bank earnings season, with JPMorgan beating expectations on both earnings and revenues driven by a surge in trading revenue amid the market’s volatile second quarter. If you're looking for stocks to hedge your portfolio, these are our Top Shorts for today.

News for Concert Pharma Stock (CNCE)